Format

Send to

Choose Destination
See comment in PubMed Commons below
Nanomedicine. 2014 Aug;10(6):1121-30. doi: 10.1016/j.nano.2014.03.004. Epub 2014 Mar 17.

Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma.

Author information

1
Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
2
Department of Surgery, Baylor College of Medicine, Houston, TX, USA; Department of Chemistry and Richard E. Smalley Institute for Nanoscale Science & Technology, Rice University, Houston, TX, USA.
3
Department of Chemistry and Richard E. Smalley Institute for Nanoscale Science & Technology, Rice University, Houston, TX, USA.
4
Department of Surgery, Baylor College of Medicine, Houston, TX, USA; Department of Mechanical Engineering and Materials Science Rice University, Houston, TX, USA. Electronic address: steven.curley@bcm.edu.

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal and chemo-refractory cancers, clearly, alternative treatment strategies are needed. We utilized 10nm gold nanoparticles as a scaffold to synthesize nanoconjugates bearing a targeting antibody (cetuximab, C225) and gemcitabine. Loading efficiency of gemcitabine on the gold nanoconjugates was 30%. Targeted gold nanoconjugates in combination with RF were selectively cytotoxic to EGFR expressing Hep3B and SNU449 cells when compared to isotype particles with/without RF (P<0.05). In animal experiments, targeted gold nanoconjugates halted the growth of subcutaneous Hep3B xenografts in combination with RF exposure (P<0.05). These xenografts also demonstrated increased apoptosis, necrosis and decreased proliferation compared to controls. Normal tissues were unharmed. We have demonstrated that non-invasive RF-induced hyperthermia when combined with targeted delivery of gemcitabine is more effective and safe at dosages ~275-fold lower than the current clinically-delivered systemic dose of gemcitabine.

FROM THE CLINICAL EDITOR:

In a model of hepatocellular carcinoma, the authors demonstrate that non-invasive RF-induced hyperthermia applied with cetuximab targeted delivery of Au NP-gemcitabine conjugate is more effective and safe at dosages ~ 275-fold lower than the current clinically-used systemic dose of gemcitabine.

KEYWORDS:

Gemcitabine; Hepatocellular; Hyperthermia; Nanoparticle; Radiofrequency

PMID:
24650884
PMCID:
PMC4349335
DOI:
10.1016/j.nano.2014.03.004
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center